Jessica Hildebrand, MD
Hematology & Oncology · Connelly Springs, NCNPI 1417248360
Payments from drug & device makers
Across 68 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$187
- AstraZeneca$114
- Johnson & Johnson$110
- Coherus Oncology, Inc.$99
- Novartis$94
- Sanofi$78
- plus $402 from 18 others
What the payments were for
- Food & beverage$1,06899%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $187 |
| AstraZeneca | 7 | $114 |
| Johnson & Johnson | 6 | $110 |
| Coherus Oncology, Inc. | 2 | $99 |
| Novartis | 6 | $94 |
| Sanofi | 4 | $78 |
| Merck | 5 | $72 |
| Lexicon Pharmaceuticals, Inc. | 3 | $42 |
| Exelixis Inc. | 3 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Boehringer Ingelheim | 2 | $28 |
| Taiho Oncology, Inc. | 2 | $24 |
| Verastem, Inc. | 2 | $22 |
| Bayer | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
| Incyte Corporation | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
| Secura Bio, Inc. | 1 | $11 |
How this compares
$1,085 in reported general payments places this provider in the 25th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 15 | $257,777 |
| Lenalidomide | 17 | $246,901 |
| ImbruvicaIbrutinib | 11 | $79,800 |
| Abiraterone Acetate | 12 | $47,453 |
| Anastrozole | 139 | $1,971 |
| Hydroxyurea | 34 | $1,274 |
| Ondansetron Hcl | 35 | $674 |
| Acyclovir | 17 | $575 |
| Dexamethasone | 44 | $511 |
| Prochlorperazine Maleate | 27 | $374 |
| Letrozole | 21 | $361 |
| Potassium Chloride | 27 | $310 |
| Omeprazole | 16 | $247 |
| Tamoxifen Citrate | 17 | $190 |
| Alendronate Sodium | 25 | $158 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Connelly Springs
- John PowderlyHuntersville$21.2M
- Kimberly BlackwellDurham$13.2M
- Joshua ZeidnerChapel Hill$11.2M
- Shelbi AtrashCharlotte$9.5M
- Matthew WieduwiltWinston Salem$9.5M
- Danielle BranderDurham$8.6M
- Jared WeissChapel Hill$7.3M
- Michael MorseDurham$6M
- Autumn McReeChapel Hill$5.5M
- Darla LilesGreenville$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.